Abrysvo

Generic name: Respiratory Syncytial Virus Vaccine
Dosage form: powder for reconstitution
Drug class: Viral vaccines

Usage of Abrysvo

Abrysvo is an RSV vaccine that is used to immunize pregnant women and adults aged 60 years and older. Abrysvo protects against developing lower respiratory tract disease (LRTD) caused by the respiratory syncytial virus (RSV) for the adults treated, and by vaccinating pregnant women, it protects infants against LRTD from birth through 6 months of age. Abrysvo works by developing immunity against two RSV proteins (antigens) RSVpreF A and RSVpreF B, so that if you get RSV, the infant or adult's immune system will be able to recognize it and destroy it.

RSV is a common, contagious virus that can cause hospitalization and death in patients that are at high risk for severe disease, which includes infants and older adults with underlying medical conditions such as diabetes and chronic heart and lung diseases.

Abrysvo became FDA-approved for adults aged 60 years and older on May 31, 2023. Abrysvo became the first RSV vaccine to be FDA-approved for pregnant women on August 21, 2023. It can be used between 32 through 36 weeks gestational age of pregnancy. It was approved for pregnant women after positive results from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy).

Abrysvo side effects

Abrysvo is generally well tolerated, and the most common side effects included fatigue, headache, injection site pain, and muscle pain. These were generally only short-lived.

Before taking Abrysvo

Do not administer the vaccine to anyone with a known history of severe allergic reactions (such as anaphylaxis) to Abrysvo or any of its components.

Relate drugs

How to use Abrysvo

Abrysvo is given by intramuscular injection, usually into the deltoid muscle of the upper arm.

The dose is 0.5mL.

Warnings

Possible anaphylactic reactions

Administer in a facility that can provide the appropriate medical treatment and supervision to manage possible anaphylactic reactions following administration.

For pregnant individuals

To avoid the potential risks of preterm birth, vaccination should be given during 32 through 36 weeks of gestational age.

In clinical trials where Abrysvo was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% Abrysvo compared to 4.4% placebo) and jaundice (7.2% Abrysvo compared to 6.7% placebo)

Syncope (fainting)

Fainting may occur following the administration of vaccines. Procedures should be in place to avoid injury from fainting.

Immunosuppression

People who are immunocompromised, including those receiving immunosuppressive therapy, may have a diminished immune response to vaccines.

Limitations

Vaccination may not protect all vaccine recipients.

Children

Abrysvo is not approved for children.

Popular FAQ

Arexvy and Abrysvo are both respiratory syncytial virus (RSV) vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age. Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults. Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.